{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Veliparib + Carboplatin + Paclitaxel",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Veliparib 120 mg BID (Days -2 to 5) in combination with Carboplatin AUC 6 (Day 1) and Paclitaxel 80 mg/m2 (Days 1, 8, 15) on a 21-day cycle. Subjects who discontinue chemotherapy without progression continue Veliparib monotherapy with titration.",
        "extensionAttributes": [
          {
            "url": "x-titration",
            "valueString": "true"
          },
          {
            "url": "x-doseEpochs",
            "valueString": "[{'dose': '120 mg BID', 'startDay': -2, 'description': 'Combination therapy phase (Days -2 through 5 of 21-day cycle)'}, {'dose': '300 mg BID', 'description': 'Single agent maintenance phase (Days 1-21 of 21-day cycle)'}, {'dose': '400 mg BID', 'description': 'Escalated single agent dose if 300 mg BID is tolerated'}]"
          }
        ]
      },
      {
        "id": "arm_2",
        "name": "Placebo + Carboplatin + Paclitaxel",
        "type": {
          "code": "Placebo Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Placebo Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Placebo BID (Days -2 to 5) in combination with Carboplatin AUC 6 (Day 1) and Paclitaxel 80 mg/m2 (Days 1, 8, 15) on a 21-day cycle. Subjects who discontinue chemotherapy without progression continue Placebo monotherapy."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_7"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_8"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_9",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_9"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_10",
        "armId": "arm_2",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_10"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Veliparib + Carboplatin + Paclitaxel - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Veliparib + Carboplatin + Paclitaxel during Screening"
      },
      {
        "id": "elem_2",
        "name": "Veliparib + Carboplatin + Paclitaxel - Blinded Study Treatment",
        "instanceType": "StudyElement",
        "description": "Treatment period for Veliparib + Carboplatin + Paclitaxel during Blinded Study Treatment"
      },
      {
        "id": "elem_3",
        "name": "Veliparib + Carboplatin + Paclitaxel - Single Agent Maintenance",
        "instanceType": "StudyElement",
        "description": "Treatment period for Veliparib + Carboplatin + Paclitaxel during Single Agent Maintenance"
      },
      {
        "id": "elem_4",
        "name": "Veliparib + Carboplatin + Paclitaxel - Unblinded Crossover",
        "instanceType": "StudyElement",
        "description": "Treatment period for Veliparib + Carboplatin + Paclitaxel during Unblinded Crossover"
      },
      {
        "id": "elem_5",
        "name": "Veliparib + Carboplatin + Paclitaxel - Post Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Veliparib + Carboplatin + Paclitaxel during Post Treatment Phase"
      },
      {
        "id": "elem_6",
        "name": "Placebo + Carboplatin + Paclitaxel - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo + Carboplatin + Paclitaxel during Screening"
      },
      {
        "id": "elem_7",
        "name": "Placebo + Carboplatin + Paclitaxel - Blinded Study Treatment",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo + Carboplatin + Paclitaxel during Blinded Study Treatment"
      },
      {
        "id": "elem_8",
        "name": "Placebo + Carboplatin + Paclitaxel - Single Agent Maintenance",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo + Carboplatin + Paclitaxel during Single Agent Maintenance"
      },
      {
        "id": "elem_9",
        "name": "Placebo + Carboplatin + Paclitaxel - Unblinded Crossover",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo + Carboplatin + Paclitaxel during Unblinded Crossover"
      },
      {
        "id": "elem_10",
        "name": "Placebo + Carboplatin + Paclitaxel - Post Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Placebo + Carboplatin + Paclitaxel during Post Treatment Phase"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 10,
      "cohortCount": 0,
      "elementCount": 10
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Double Blind",
        "codeSystem": "USDM",
        "decode": "Double Blind"
      },
      "maskedRoles": [
        "Subject",
        "Investigator"
      ],
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "2:1"
      },
      "stratificationFactors": [
        "Estrogen receptor (ER) and/or progesterone receptor (PgR) positive versus ER/PgR negative",
        "Prior platinum therapy (yes versus no)",
        "CNS metastases (yes versus no)"
      ],
      "controlType": {
        "code": "Placebo Control",
        "codeSystem": "USDM",
        "decode": "Placebo Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "therapeuticAreas": [
        "Oncology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Double Blind",
        "maskedRoles": [
          "Subject",
          "Investigator"
        ]
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "2:1",
        "stratificationFactors": [
          "Estrogen receptor (ER) and/or progesterone receptor (PgR) positive versus ER/PgR negative",
          "Prior platinum therapy (yes versus no)",
          "CNS metastases (yes versus no)"
        ]
      },
      "controlType": "Placebo",
      "therapeuticAreas": [
        "Oncology"
      ]
    },
    "arms": [
      {
        "name": "Veliparib + Carboplatin + Paclitaxel",
        "type": "Experimental Arm",
        "description": "Veliparib 120 mg BID (Days -2 to 5) in combination with Carboplatin AUC 6 (Day 1) and Paclitaxel 80 mg/m2 (Days 1, 8, 15) on a 21-day cycle. Subjects who discontinue chemotherapy without progression continue Veliparib monotherapy with titration.",
        "isTitration": true,
        "doseEpochs": [
          {
            "dose": "120 mg BID",
            "startDay": -2,
            "endDay": null,
            "description": "Combination therapy phase (Days -2 through 5 of 21-day cycle)"
          },
          {
            "dose": "300 mg BID",
            "startDay": null,
            "endDay": null,
            "description": "Single agent maintenance phase (Days 1-21 of 21-day cycle)"
          },
          {
            "dose": "400 mg BID",
            "startDay": null,
            "endDay": null,
            "description": "Escalated single agent dose if 300 mg BID is tolerated"
          }
        ]
      },
      {
        "name": "Placebo + Carboplatin + Paclitaxel",
        "type": "Placebo Comparator",
        "description": "Placebo BID (Days -2 to 5) in combination with Carboplatin AUC 6 (Day 1) and Paclitaxel 80 mg/m2 (Days 1, 8, 15) on a 21-day cycle. Subjects who discontinue chemotherapy without progression continue Placebo monotherapy.",
        "isTitration": false,
        "doseEpochs": null
      }
    ],
    "cohorts": [],
    "epochs": [
      {
        "name": "Screening",
        "description": "Up to 28 days prior to randomization"
      },
      {
        "name": "Blinded Study Treatment",
        "description": "Combination therapy with Carboplatin and Paclitaxel"
      },
      {
        "name": "Single Agent Maintenance",
        "description": "Veliparib or Placebo monotherapy following discontinuation of chemotherapy without progression"
      },
      {
        "name": "Unblinded Crossover",
        "description": "Optional crossover to unblinded veliparib monotherapy for placebo subjects after documented disease progression"
      },
      {
        "name": "Post Treatment Phase",
        "description": "Follow-up for survival and subsequent therapies every 2 months"
      }
    ]
  }
}